TY - JOUR
T1 - Neutralizing Aptamers Block S/RBD-ACE2 Interactions and Prevent Host Cell Infection
AU - Liu, Xiaohui
AU - Wang, Yi ling
AU - Wu, Jacky
AU - Qi, Jianjun
AU - Zeng, Zihua
AU - Wan, Quanyuan
AU - Chen, Zhenghu
AU - Manandhar, Pragya
AU - Cavener, Victoria S.
AU - Boyle, Nina R.
AU - Fu, Xinping
AU - Salazar, Eric
AU - Kuchipudi, Suresh V.
AU - Kapur, Vivek
AU - Zhang, Xiaoliu
AU - Umetani, Michihisa
AU - Sen, Mehmet
AU - Willson, Richard C.
AU - Chen, Shu hsia
AU - Zu, Youli
N1 - Publisher Copyright:
© 2021 Wiley-VCH GmbH
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
© 2021 Wiley-VCH GmbH.
PY - 2021/4/26
Y1 - 2021/4/26
N2 - The receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 spike (S) protein plays a central role in mediating the first step of virus infection to cause disease: virus binding to angiotensin-converting enzyme 2 (ACE2) receptors on human host cells. Therefore, S/RBD is an ideal target for blocking and neutralization therapies to prevent and treat coronavirus disease 2019 (COVID-19). Using a target-based selection approach, we developed oligonucleotide aptamers containing a conserved sequence motif that specifically targets S/RBD. Synthetic aptamers had high binding affinity for S/RBD-coated virus mimics (KD≈7 nM) and also blocked interaction of S/RBD with ACE2 receptors (IC50≈5 nM). Importantly, aptamers were able to neutralize S protein-expressing viral particles and prevent host cell infection, suggesting a promising COVID-19 therapy strategy.
AB - The receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 spike (S) protein plays a central role in mediating the first step of virus infection to cause disease: virus binding to angiotensin-converting enzyme 2 (ACE2) receptors on human host cells. Therefore, S/RBD is an ideal target for blocking and neutralization therapies to prevent and treat coronavirus disease 2019 (COVID-19). Using a target-based selection approach, we developed oligonucleotide aptamers containing a conserved sequence motif that specifically targets S/RBD. Synthetic aptamers had high binding affinity for S/RBD-coated virus mimics (KD≈7 nM) and also blocked interaction of S/RBD with ACE2 receptors (IC50≈5 nM). Importantly, aptamers were able to neutralize S protein-expressing viral particles and prevent host cell infection, suggesting a promising COVID-19 therapy strategy.
KW - COVID-19
KW - SARS-CoV-2
KW - aptamers
KW - receptor-binding domain (RBD)
KW - virus neutralization
KW - COVID-19/drug therapy
KW - Antiviral Agents/chemistry
KW - Humans
KW - Angiotensin-Converting Enzyme 2/metabolism
KW - Spike Glycoprotein, Coronavirus/chemistry
KW - SARS-CoV-2/chemistry
KW - Protein Interaction Maps/drug effects
KW - Base Sequence
KW - HEK293 Cells
KW - Aptamers, Nucleotide/chemistry
KW - Protein Interaction Domains and Motifs/drug effects
UR - http://www.scopus.com/inward/record.url?scp=85102840060&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102840060&partnerID=8YFLogxK
U2 - 10.1002/anie.202100345
DO - 10.1002/anie.202100345
M3 - Article
C2 - 33684258
AN - SCOPUS:85102840060
SN - 1433-7851
VL - 60
SP - 10273
EP - 10278
JO - Angewandte Chemie - International Edition
JF - Angewandte Chemie - International Edition
IS - 18
ER -